Probability of C282Y homozygosity decreases as liver transaminase activities increase in participants with hyperferritinemia in the hemochromatosis and iron overload screening study
- PMID: 22183642
- PMCID: PMC3355194
- DOI: 10.1002/hep.25538
Probability of C282Y homozygosity decreases as liver transaminase activities increase in participants with hyperferritinemia in the hemochromatosis and iron overload screening study
Abstract
Hemochromatosis is considered by many to be an uncommon disorder, although the prevalence of HFE (High Iron) 282 Cys → Tyr (C282Y) homozygosity is relatively high in Caucasians. Liver disease is one of the most consistent findings in advanced iron overload resulting from hemochromatosis. Liver clinics are often thought to be ideal venues for diagnosis of hemochromatosis, but diagnosis rates are often low. The Hemochromatosis and Iron Overload Screening (HEIRS) Study screened 99,711 primary care participants in North America for iron overload using serum ferritin and transferrin saturation measurements and HFE genotyping. In this HEIRS substudy, serum hepatic transaminases activities (e.g., alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) were compared between 162 C282Y homozygotes and 1,367 nonhomozygotes with serum ferritin levels >300 μg/L in men and >200 μg/L in women and transferrin saturation >45% in women and 50% in men. The probability of being a C282Y homozygote was determined for AST and ALT ranges. Mean ALT and AST activities were significantly lower in C282Y homozygotes than nonhomozygotes. The probability of being a C282Y homozygote increased as the ALT and AST activities decreased.
Conclusion: Patients with hyperferritinemia are more likely to be C282Y homozygotes if they have normal liver transaminase activities. This paradox could explain the low yields of hemochromatosis screening reported by some liver clinics.
Copyright © 2012 American Association for the Study of Liver Diseases.
Figures
Similar articles
-
Hemochromatosis and iron-overload screening in a racially diverse population.N Engl J Med. 2005 Apr 28;352(17):1769-78. doi: 10.1056/NEJMoa041534. N Engl J Med. 2005. PMID: 15858186
-
HFE C282Y homozygotes aged 25-29 years at HEIRS Study initial screening.Genet Test. 2007 Fall;11(3):269-75. doi: 10.1089/gte.2007.0003. Genet Test. 2007. PMID: 17949288
-
HFE mutations in Caucasian participants of the Hemochromatosis and Iron Overload Screening study with serum ferritin level <1000 µg/L.Can J Gastroenterol. 2013 Jul;27(7):390-2. doi: 10.1155/2013/493170. Can J Gastroenterol. 2013. PMID: 23862168 Free PMC article.
-
Epidemiology and diagnostic testing for hemochromatosis and iron overload.Int J Lab Hematol. 2015 May;37 Suppl 1:25-30. doi: 10.1111/ijlh.12347. Int J Lab Hematol. 2015. PMID: 25976957 Review.
-
Hereditary hemochromatosis.Am Fam Physician. 2013 Feb 1;87(3):183-90. Am Fam Physician. 2013. PMID: 23418762 Review.
Cited by
-
Genetic disruption of NRF2 promotes the development of necroinflammation and liver fibrosis in a mouse model of HFE-hereditary hemochromatosis.Redox Biol. 2017 Apr;11:157-169. doi: 10.1016/j.redox.2016.11.013. Epub 2016 Dec 1. Redox Biol. 2017. PMID: 27936457 Free PMC article.
-
Hereditary hemochromatosis.Autops Case Rep. 2015 Mar 30;5(1):7-10. doi: 10.4322/acr.2014.043. eCollection 2015 Jan-Mar. Autops Case Rep. 2015. PMID: 26484318 Free PMC article. No abstract available.
-
Elevated serum transaminase activities were associated with increased serum levels of iron regulatory hormone hepcidin and hyperferritinemia risk.Sci Rep. 2015 Aug 20;5:13106. doi: 10.1038/srep13106. Sci Rep. 2015. PMID: 26290281 Free PMC article.
-
EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH).Eur J Hum Genet. 2016 Apr;24(4):479-95. doi: 10.1038/ejhg.2015.128. Epub 2015 Jul 8. Eur J Hum Genet. 2016. PMID: 26153218 Free PMC article.
-
Predicting C282Y homozygote genotype for hemochromatosis using serum ferritin and transferrin saturation values from 44,809 participants of the HEIRS study.Can J Gastroenterol Hepatol. 2014 Oct;28(9):502-4. doi: 10.1155/2014/698352. Can J Gastroenterol Hepatol. 2014. PMID: 25314357 Free PMC article.
References
-
- Adams PC, Barton JC. How I treat hemochromatosis. Blood. 2010;116:317–325. - PubMed
-
- Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, et al. Hemochromatosis and Iron-Overload Screening in a Racially Diverse Population. N Engl J Med. 2005;352:1769–1778. - PubMed
-
- Adams PC, Passmore L, Chakrabarti S, Reboussin D, Acton R, Barton J, et al. Liver diseases in the Hemochromatosis and Iron Overload Screening Study. Clin Gastroenterol Hepatol. 2006;4:918–923. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- N01-HC-05188/HC/NHLBI NIH HHS/United States
- N01HC05188/HC/NHLBI NIH HHS/United States
- N01 HC005192/HC/NHLBI NIH HHS/United States
- N01-HC-05186/HC/NHLBI NIH HHS/United States
- N01HC05185/HC/NHLBI NIH HHS/United States
- N01 HC005191/HC/NHLBI NIH HHS/United States
- N01-HC-05191/HC/NHLBI NIH HHS/United States
- N01-HC-05190/HC/NHLBI NIH HHS/United States
- N01HC05190/HC/NHLBI NIH HHS/United States
- N01-HC-05189/HC/NHLBI NIH HHS/United States
- N01HC05189/HC/NHLBI NIH HHS/United States
- N01HC05191/HC/NHLBI NIH HHS/United States
- P30 CA062203/CA/NCI NIH HHS/United States
- N01HC05186/HC/NHLBI NIH HHS/United States
- N01-HC-05185/HC/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical